Board Change

 

TIDMONG 
 
RNS Number : 7512H 
Oxford Nutrascience Group PLC 
01 March 2010 
 

1 March 2010 
  Oxford Nutrascience Group Plc 
 
 ("Oxford Nutrascience" or the "Company") 
 
Board changes 
 
 The Company announces that Marcelo Bravo, Non Executive Chairman of Oxford 
Nutrascience is to become Executive Chairman with immediate effect. Marcelo 
spent 16 years in R&D with The Procter & Gamble Company and subsequently spent 
three years in corporate development with Boots (now Boots Alliance) and is also 
an experienced entrepreneur. 
 
 The Company intends  to appoint an 
additional Non-Executive Director and an announcement will be made as and when 
appropriate. 
 
Nigel Theobald, Chief Executive, Oxford Nutrascience Group Plc commented: 
 
"The Company is looking to work with a number of the major brand owners in 
the Over the Counter and prescription pharmaceutical sectors. Marcelo has 
considerable experience of these companies and we look forward to benefiting 
from his increased contribution." 
 
 
For further information 
 
Oxford Nutrascience Group Plc                                     +44 1865 
854874 
Nigel Theobald (Chief Executive Officer) 
Mark Way (Investor and Media relations)                    [phone] 
 
ZAI Corporate Finance (Nominated Adviser)              [phone] 
David Newton 
 
www.oxfordnutrascience.com 
 
 
 
About Oxford Nutrascience Group Plc 
 
·      Oxford Nutrascience is a UK consumer healthcare company that develops 
chewy confectionery, chewable tablets and liquid suspensions to allow medicines 
and vitamin supplements to be taken in a more pleasant and convenient way. 
 
·      Oxford Nutrascience has developed technology for the use of prebiotic 
soluble fibres in medicine delivery systems that disperse and solubilise 
medicines, improve taste and mouth feel, simplify processing and eliminate 
additives, incorporate prebiotic health benefits. 
 
·      Chews: Oxford Nutrascience currently produces Ellactiva , a calcium chewy 
supplement sold in the UK and in the Middle East, and plans to launch new chews 
to complement this existing product. 
 
·      Chewable tablets and liquid suspensions: The target market for Oxford 
Nutrasciences' Chewitabs(TM) and liquid suspension delivery systems are 
over-the-counter ("OTC") pain relieving drugs, indigestion preparations and 
cough and cold medicines. 
 
·      Oxford Nutrascience's medicine development work is currently focused on 
ibuprofen suspension and chewable allergy tablets incorporating loratadine. 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 BOAUNUARRNAUUAR